A branded generic is a generic drug that has gone through the ANDA process, and is assigned a name other than its chemical name. These branded generic drugs may be developed by a generic drug company or by original manufacturers after patent expiration. A branded generic name is owned by the company that manufactures or sells it. It must be bioequivalent to original brand products. Branded generics may not be as inexpensive as a regular generic, but they may be less expensive than original brands. According to the Association for Accessible Medicines, brand-name companies make about half of the generic drugs present in the market.
COVID-19 scenario analysis:
Pharmaceutical and biotechnological companies together with governments around the globe are working to combat the COVID-19 outbreak. This is carried out by supporting development of vaccines to schedule for medicines supply chain challenges. Furthermore, there are around 115 vaccine candidates and other 155 molecules that are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have seen huge boost in demand for management of COVID-19. There is an increase in demand for the drug, which has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of the drug. Hence, owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is anticipated to witness a substantial growth in the next few years.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis
The major factor affecting the industry includes large number of pharmaceutical products that are going to go off-patent. This would help the industry to propel in the next few years. Growth in number of patents expired and expiring for branded drugs are anticipated to boost the industry in the coming years. The increase in incidents and population suffering from chronic diseases and disorders would help the industry gain traction during the forecast period.
Growth in number of product launches to boost the market
Growth in number of product launches would help the industry flourish during the forecast period. For instance, in July 2019, Amneal Pharmaceuticals, Inc. announced that it received approval for and launched its generic version of Lyrica (pregabalin capsules) 25 mg, 50 mg, 75, mg, 100 mg, 150 mg, 200 mg, 225 mg, and 300 mg. This new generic launch provides an important treatment option for patients and as twenty-first generic product launch this year, demonstrates continues momentum of the generic pipeline.
In July 2020, Sol-Gel Technologies, Ltd., a clinical-stage dermatology company focused on identifying, developing, and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that Sol-Gel has been informed by its collaboration partner that the launch of an FDA-approved generic drug is expected in the second quarter of 2021. In 2019, sales of the brand name product exceeded $180 million in the United States. Per terms of the previously announced collaboration agreement, Sol-Gel will receive payments based on product sales beginning at the launch date.
Surge in number of mergers and acquisitions to propel the market
Rise in number of mergers and acquisitions is anticipated to help the industry grow in the coming years. For instance, in March 2020, Hyderabad-based pharma major Dr Reddy’s Laboratories bought Wockhardt Ltd.’s branded generics business in India, Nepal, Sri Lanka, Bhutan, and Maldives and its manufacturing plant at Baddi in Himachal Pradesh for around Rs 1,850 crore. Wockhardt is selling a part of the business as it plans to ensure adequate liquidity. Dr Reddy’s is paying more than three times of the revenues that Wockhardt’s business generates.
In the due course, Wockhardt’s strategic plan is to shift from acute therapeutic areas to more chronic businesses such as anti-diabetes and central nervous system into niche antibiotic portfolios. The sell-off will fetch Wockhardt adequate liquidity for investing in growing business both in India and abroad.
The Wockhardt’s business, which is changing hands is pegged around revenue of Rs 370 crore December and around Rs 600 crore in 2018–2019. In fact, in 2018–2019, the divested portfolio constituted 28% of standalone revenue and 14% of the consolidated revenue.
Key benefits of the report:
- This study presents the analytical depiction of the global branded generics industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global branded generics market share.
- The current market is quantitatively analyzed to highlight the global Branded Generics market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the Branded Generics market.
- The report provides a detailed global branded generics market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the branded generics market research report:
- Which are the leading market players active in the branded generics market?
- What would be the detailed impact of COVID-19 on the Branded Generics market?
- What current trends would influence the Branded Generics market in the next few years?
- What are the driving factors, restraints, and opportunities in the branded generics market?
- What are the projections for the future that would help in taking further strategic steps?
Branded Generics Market, by Product Type Report Highlights
| Aspects | Details |
 By Product Type |
|
 By Consumption Type |
|
 By Distribution Channel |
|
 By Drug Class |
|
 By Region |
|
 Key Market Players | Lupin Pharmaceuticals, Inc., Apotex Inc.,, Sandoz,, Valeant,, Mylan N.V.,, AstraZeneca., Dr. Reddy’s Laboratories Ltd.,, ZydusCadila,, Teva Pharmaceutical Industries Ltd,, GlaxoSmithKline Pharmaceuticals Limited,, Sanofi,, Hospira Inc., |
Loading Table Of Content...
